WORCESTER, Mass.--(BUSINESS WIRE)--RXi Pharmaceuticals Corporation (Nasdaq: RXII), a recognized leader in RNAi-based therapeutic discovery and development, today announced the company’s new focused RNAi therapeutic strategy at the Jefferies 2010 Global Life Sciences Conference.
